Heron Therapeutics, Inc.
HRTX
$0.40
-$0.05-10.74%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.71M | 40.59M | 38.21M | 37.20M | 38.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.71M | 40.59M | 38.21M | 37.20M | 38.90M |
| Cost of Revenue | 13.02M | 14.87M | 15.38M | 12.79M | 10.74M |
| Gross Profit | 21.69M | 25.72M | 22.83M | 24.41M | 28.17M |
| SG&A Expenses | 26.45M | 25.69M | 26.92M | 26.05M | 25.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.48M | 40.55M | 42.31M | 38.84M | 35.75M |
| Operating Income | -4.77M | 38.00K | -4.09M | -1.64M | 3.15M |
| Income Before Tax | -8.11M | -2.95M | -17.50M | -2.38M | 2.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.11M | -2.95M | -17.50M | -2.38M | 2.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.11M | -2.95M | -17.50M | -2.38M | 2.64M |
| EBIT | -4.77M | 38.00K | -4.09M | -1.64M | 3.15M |
| EBITDA | -4.24M | 575.00K | -3.48M | -1.03M | 3.71M |
| EPS Basic | -0.04 | -0.02 | -0.10 | -0.02 | 0.02 |
| Normalized Basic EPS | -0.03 | -0.01 | -0.02 | -0.01 | 0.01 |
| EPS Diluted | -0.04 | -0.02 | -0.10 | -0.02 | 0.01 |
| Normalized Diluted EPS | -0.03 | -0.01 | -0.02 | -0.01 | 0.01 |
| Average Basic Shares Outstanding | 189.65M | 188.03M | 170.35M | 154.02M | 153.49M |
| Average Diluted Shares Outstanding | 189.65M | 188.03M | 170.35M | 154.02M | 196.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |